CL2020001990A1 - Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20) - Google Patents

Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20)

Info

Publication number
CL2020001990A1
CL2020001990A1 CL2020001990A CL2020001990A CL2020001990A1 CL 2020001990 A1 CL2020001990 A1 CL 2020001990A1 CL 2020001990 A CL2020001990 A CL 2020001990A CL 2020001990 A CL2020001990 A CL 2020001990A CL 2020001990 A1 CL2020001990 A1 CL 2020001990A1
Authority
CL
Chile
Prior art keywords
nmda receptor
spiro
receptor modulators
lactam nmda
lactam
Prior art date
Application number
CL2020001990A
Other languages
English (en)
Spanish (es)
Inventor
M Amin Khan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2020001990A1 publication Critical patent/CL2020001990A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2020001990A 2018-01-31 2020-07-30 Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20) CL2020001990A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624218P 2018-01-31 2018-01-31
US201862718107P 2018-08-13 2018-08-13

Publications (1)

Publication Number Publication Date
CL2020001990A1 true CL2020001990A1 (es) 2021-03-26

Family

ID=65494516

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001990A CL2020001990A1 (es) 2018-01-31 2020-07-30 Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20)

Country Status (15)

Country Link
US (1) US20210047324A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746442A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021512109A (cg-RX-API-DMAC7.html)
KR (1) KR20200115610A (cg-RX-API-DMAC7.html)
CN (1) CN112218866A (cg-RX-API-DMAC7.html)
AU (1) AU2019215049A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015666A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089559A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001990A1 (cg-RX-API-DMAC7.html)
IL (1) IL276330A (cg-RX-API-DMAC7.html)
MX (1) MX2020008106A (cg-RX-API-DMAC7.html)
PE (1) PE20211455A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551140A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007251XA (cg-RX-API-DMAC7.html)
WO (1) WO2019152678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2024054919A1 (en) * 2022-09-08 2024-03-14 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
AU2024354932A1 (en) * 2023-10-03 2026-04-09 Revolution Medicines, Inc. Synthesis of ras inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
SG10201501050RA (en) * 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技(上海)有限公司 一种制备二氮杂螺环化合物的方法
JP6419087B2 (ja) * 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体モジュレーターおよびその使用
SG11201505937SA (en) * 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
CA2898861C (en) * 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN105308049A (zh) * 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3277690B1 (en) * 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
PE20190174A1 (es) * 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) * 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AR110988A1 (es) * 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
JP2022092387A (ja) * 2020-12-10 2022-06-22 キヤノン株式会社 画像形成装置

Also Published As

Publication number Publication date
AU2019215049A1 (en) 2020-09-17
BR112020015666A2 (pt) 2021-02-23
EP3746442A1 (en) 2020-12-09
MX2020008106A (es) 2020-09-25
PH12020551140A1 (en) 2021-05-31
JP2021512109A (ja) 2021-05-13
CN112218866A (zh) 2021-01-12
JP2024019396A (ja) 2024-02-09
SG11202007251XA (en) 2020-08-28
PE20211455A1 (es) 2021-08-05
WO2019152678A1 (en) 2019-08-08
IL276330A (en) 2020-09-30
US20210047324A1 (en) 2021-02-18
KR20200115610A (ko) 2020-10-07
CA3089559A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
CL2020001991A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1990-20)
MX2018014202A (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
ECSP19029982A (es) Moduladores de calpaínas y usos terapeuticos de los mismos
PY1947754A (es) Piridinil y pirazinil-(aza)indolsulfonamidas
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX390120B (es) Moduladores de la somatostatina y usos de los mismos.
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
MX2017014375A (es) Moduladores del ccr2.
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CR20190239A (es) Inhibidores de la magl
CL2021003257A1 (es) Pirazolo-piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
ECSP21090478A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
MX394318B (es) Inhibidores pirazolicos de magl
PH12019500949A1 (en) Ror-gamma modulators
MX2018014135A (es) Tratamiento del dolor.
MX2017009164A (es) Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.
CL2023001608A1 (es) Moduladores de progranulina y métodos de uso de los mismos
MX2016005510A (es) Profarmacos y moduladores de receptores nmda, sales y usos de estos.
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
CL2013000409A1 (es) Compuestos derivados de (piridin-2-il)-metano y (pirimidin-2-il)-metanol, moduladores del receptor de potencial transitorio vainilloide 3 (trpv3); composicion farmaceutica; utiles en el tratamiento del dolor.